share_log

Even Though Twist Bioscience (NASDAQ:TWST) Has Lost US$154m Market Cap in Last 7 Days, Shareholders Are Still up 193% Over 1 Year

Even Though Twist Bioscience (NASDAQ:TWST) Has Lost US$154m Market Cap in Last 7 Days, Shareholders Are Still up 193% Over 1 Year

儘管Twist Bioscience(納斯達克股票代碼:TWST)在過去7天內損失了1.54億美元的市值,但股東在1年內仍上漲了193%
Simply Wall St ·  05/27 23:57

When you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right stock, you can make a lot more than 100%. For example, the Twist Bioscience Corporation (NASDAQ:TWST) share price has soared 193% return in just a single year. It's also up 34% in about a month. We note that Twist Bioscience reported its financial results recently; luckily, you can catch up on the latest revenue and profit numbers in our company report. Unfortunately the longer term returns are not so good, with the stock falling 61% in the last three years.

當你購買公司的股票時,總是存在價格跌至零的風險。但是,如果你選擇了正確的股票,你可以賺很多錢 更多 超過 100%。例如,Twist Bioscience Corporation(納斯達克股票代碼:TWST)的股價在短短一年內就飆升了193%的回報率。它在大約一個月內也上漲了34%。我們注意到,Twist Bioscience最近公佈了其財務業績;幸運的是,您可以在我們的公司報告中了解最新的收入和利潤數字。不幸的是,長期回報並不那麼好,該股在過去三年中下跌了61%。

While the stock has fallen 5.9% this week, it's worth focusing on the longer term and seeing if the stocks historical returns have been driven by the underlying fundamentals.

儘管該股本週下跌了5.9%,但值得關注長期情況,看看股票的歷史回報是否是由基礎基本面推動的。

Twist Bioscience isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally hope to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

Twist Bioscience目前沒有盈利,因此大多數分析師會着眼於收入的增長,以了解基礎業務的增長速度。當一家公司沒有盈利時,我們通常希望看到良好的收入增長。可以想象,收入的快速增長如果持續下去,通常會帶來利潤的快速增長。

Twist Bioscience grew its revenue by 22% last year. That's a fairly respectable growth rate. While that revenue growth is pretty good the share price performance outshone it, with a lift of 193% as mentioned above. If the profitability is on the horizon then now could be a very exciting time to be a shareholder. But investors need to be wary of how the 'fear of missing out' could influence them to buy without doing thorough research.

去年,Twist Bioscience的收入增長了22%。這是一個相當可觀的增長率。儘管收入增長相當不錯,但股價表現卻超過了它,如上所述,增長了193%。如果盈利即將到來,那麼現在成爲股東可能是一個非常激動人心的時刻。但是,投資者需要警惕 “害怕錯過機會” 會如何影響他們在沒有進行深入研究的情況下買入。

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

您可以在下圖中看到收入和收入隨時間推移而發生的變化(點擊圖表查看確切值)。

earnings-and-revenue-growth
NasdaqGS:TWST Earnings and Revenue Growth May 27th 2024
納斯達克GS:TWST 收益和收入增長 2024 年 5 月 27 日

This free interactive report on Twist Bioscience's balance sheet strength is a great place to start, if you want to investigate the stock further.

如果你想進一步調查該股,這份關於Twist Bioscience資產負債表實力的免費互動報告是一個很好的起點。

A Different Perspective

不同的視角

We're pleased to report that Twist Bioscience shareholders have received a total shareholder return of 193% over one year. Since the one-year TSR is better than the five-year TSR (the latter coming in at 10% per year), it would seem that the stock's performance has improved in recent times. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Take risks, for example - Twist Bioscience has 3 warning signs we think you should be aware of.

我們很高興地向大家報告,Twist Bioscience的股東在一年內獲得了193%的總股東回報率。由於一年期股東總回報率好於五年期股東總回報率(後者爲每年10%),因此該股的表現似乎在最近有所改善。持樂觀態度的人可能會將最近股東總回報率的改善視爲業務本身隨着時間的推移而變得更好。儘管市場狀況可能對股價產生的不同影響值得考慮,但還有其他因素更爲重要。例如,冒險吧——Twist Bioscience有3個警告信號,我們認爲你應該注意。

Of course Twist Bioscience may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

當然,Twist Bioscience可能不是最好的買入股票。因此,您可能希望看到這批免費的成長股。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文引用的市場回報反映了目前在美國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論